Surrozen submits IND for SZN-8141
Analysis based on 7 articles · First reported Sep 08, 2026 · Last updated Sep 08, 2026
The IND submission is a positive regulatory milestone for Surrozen, potentially advancing its lead candidate toward clinical trials and validating its Wnt-based platform. However, the stock traded down 1.98% to $22.31, reflecting modest market reaction and the early-stage nature of the development.
Surrozen, Inc. announced the submission of an Investigational New Drug (IND) application to the U.S. United States — Food and Drug Administration for SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema (DME). The company plans to evaluate SZN-8141 in the DUET Phase 1b/2a clinical trial, expected to initiate by year-end 2026 with initial data anticipated in the second half of 2027. Preclinical studies showed SZN-8141 reduced neovascularization and vascular leakage more effectively than monotherapies. Surrozen aims to differentiate SZN-8141 from existing anti-VEGF therapies by combining Wnt pathway activation with VEGF inhibition.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard